Sex steroids have potent effects on mood, mental state and cognition. Our previous findings and those of others suggest that these effects may be due at least in part to estradiol actions on central serotonergic mechanisms. Specifically, estradiol-17beta in its acute positive feedback mode for gonadotropin release in the female rat induces expression of the genes for the 5-hydroxytryptamine(2A) receptor (5-HT(2A)R) and the serotonin transporter (SERT) in the dorsal raphe nucleus (DRN). This is accompanied by an increase in the densities of 5-HT(2A)R and the SERT in forebrain regions which in the human are concerned with the control of mood, mental state, cognition and emotion. Here we report that raloxifene, a benzothiophene and selective estrogen receptor modulator (SERM), completely blocked estradiol stimulation of brain 5-HT(2A)R and SERT expression in acutely ovariectomized rats. Raloxifene also blocked the estrogen-induced surge of luteinizing hormone. Treatment of acutely ovariectomized rats with raloxifene alone increased the density of SERT sites in the mid-frontal cortex and decreased the density of 5-HT(2A)R in the posterior olfactory tubercle. The inhibitory effects of raloxifene on acute estrogen-induction of central serotonergic mechanisms were similar to those of tamoxifen even though there are major differences between the two SERMs in their affinity for the two estrogen receptor subtypes and their actions on the uterus. These findings provide robust evidence that estradiol induction of the 5-HT(2A)R and the SERT in brain is mediated by nuclear estrogen receptors. Our data may provide the basis for obtaining a better understanding of the effects of sex steroids on mood and mental state in the human and the possible rational development of congeners of sex steroids for the treatment of mental disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neulet.2007.02.039 | DOI Listing |
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
Background: Increased stress, a proposed risk factor for Alzheimer's disease (AD), is associated with increased brain and cognitive vulnerabilities in older populations, which may be different in women and men.
Objective: To examine cross-sectional associations between circulating stress hormones (epinephrine, norepinephrine, cortisol, dehydroepiandrosterone sulfate (DHEAS), and DHEAS/cortisol ratio) and multimodal measures of brain health and cognition sensitive to AD.
Method: 132 cognitively unimpaired older participants without clinical depression (age = 74.
Background: Alzheimer's Disease (AD) is a complex neurodegenerative disease characterized by multiple etiologies that remains without a cure. Diabetes, dyslipidemia, hypertension, and inflammation are well-known risk factors for AD, and FDA-approved therapeutics for these conditions have been associated with a reduced risk of developing AD. This study aims to evaluate the impact of diabetes medications (DBMD), lipid-lowering (LIPL), antihypertensive (AHTN), and non-steroidal anti-inflammatory (NSD) therapeutics, alone or combined, on cognitive performance in an AD population.
View Article and Find Full Text PDFRev Esp Enferm Dig
January 2025
Gastroenterology , Hospital Álvaro Cunqueiro, España.
Background: The absence of proper ergonomics in digestive endoscopy, combined with an increasing workload, has contributed to a growing incidence of musculoskeletal complaints among endoscopists. This study aims to assess the frequency of musculoskeletal complaints and their impact on clinical practice among Spanish endoscopists.
Methods: An electronic survey was sent to active members of the Spanish Society of Digestive Endoscopy (SEED) in July 2019.
Background: Low levels of high density lipoprotein cholesterol (HDL-c) are a risk factors for atherosclerotic cardiovascular disease (ASCVD). ASCVD can increase the risk for dementia. However, the link between HDL-C and incidence of dementia remain less clear specifically in women.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: There is an urgent need to identify novel, accessible and affordable strategies to prevent cognitive decline and progression in the Alzheimer disease and related dementias (ADRD) continuum. Vitamin D3 and marine omega-3 fatty acids (omega-3s) supplements show promise for cognitive protection, with potential variations in their effects by sex or race. However, to date, no randomized clinical trials (RCTs) have tested their impact on emerging plasma-based biomarkers with potential utility to predict ADRD pathogenesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!